Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Aggregates Not Visible with Naked Eye Detected in Kenacort
April 6, 2009
- Mr Matsutani to Step Down as FJPWA President
April 6, 2009
- Pfizer Announces Results of EPPV on Sutent
April 6, 2009
- NEW PRODUCTS
April 6, 2009
- Greater Hypotensive Effects Can Be Expected with Co-DIO: Dr Ogihara
April 6, 2009
- BUSINESS NEWS IN BRIEF
April 6, 2009
- Selective a1-Inhibitors Effective against MS-Associated Dysuria: Prof. Horie
April 6, 2009
- GENERICS NEWS IN BRIEF
March 30, 2009
- The First Round Results of GE Amlodipine (1) - Making No Surprise Moves Leads to Success -
March 30, 2009
- Astellas to Enhance Its Presence as "National Flag Pharma"
March 30, 2009
- Astellas, Shionogi Enthusiastic about Joint Research with Academia
March 30, 2009
- Studies Voluntarily Conducted by Physicians Must Be Funded by Contracts
March 30, 2009
- Takara Bio Supplies RetroNectin for 46th Clinical Trial
March 30, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 30, 2009
- JAPhMed to Be Incorporated into Medical Society in April
March 30, 2009
- Takara Bio Licenses LA-PCR Methods to Biotools of Spain
March 30, 2009
- LDP Diet Members Not Persuaded about Safety of Online Sale
March 30, 2009
- Tanaka Kikinzoku Develops Flu Virus Detection Reagent Using Gold Particles
March 30, 2009
- Mr Ishii of JPA Rages at Mr Mikitani
March 30, 2009
- Asubio Pharma to Specialize in Drug Discovery
March 30, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…